397 related articles for article (PubMed ID: 19568409)
1. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
Réjiba S; Bigand C; Parmentier C; Hajri A
Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth.
Vernejoul F; Ghénassia L; Souque A; Lulka H; Drocourt D; Cordelier P; Pradayrol L; Pyronnet S; Buscail L; Tiraby G
Mol Ther; 2006 Dec; 14(6):758-67. PubMed ID: 17000136
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
6. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
[TBL] [Abstract][Full Text] [Related]
7. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
8. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
Fujiwara Y; Shiba H; Iwase R; Haruki K; Furukawa K; Uwagawa T; Misawa T; Ohashi T; Yanaga K
J Am Coll Surg; 2013 Feb; 216(2):320-32.e3. PubMed ID: 23219147
[TBL] [Abstract][Full Text] [Related]
11. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
[TBL] [Abstract][Full Text] [Related]
13. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral vector transduction of the human deoxycytidine kinase gene enhances the cytotoxic and radiosensitizing effect of gemcitabine on experimental gliomas.
Szatmári T; Huszty G; Désaknai S; Spasokoukotskaja T; Sasvári-Székely M; Staub M; Esik O; Sáfrány G; Lumniczky K
Cancer Gene Ther; 2008 Mar; 15(3):154-64. PubMed ID: 18188186
[TBL] [Abstract][Full Text] [Related]
16. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
[TBL] [Abstract][Full Text] [Related]
17. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
Grégoire V; Rosier JF; De Bast M; Bruniaux M; De Coster B; Octave-Prignot M; Scalliet P
Radiother Oncol; 2002 Jun; 63(3):329-38. PubMed ID: 12142097
[TBL] [Abstract][Full Text] [Related]
18. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
[TBL] [Abstract][Full Text] [Related]
19. siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.
Di Cresce C; Figueredo R; Rytelewski M; Maleki Vareki S; Way C; Ferguson PJ; Vincent MD; Koropatnick J
Oncotarget; 2015 Sep; 6(26):22397-409. PubMed ID: 26087398
[TBL] [Abstract][Full Text] [Related]
20. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
